These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 39172318)

  • 1. Comparative Cost-Effectiveness of Gemcitabine and Cisplatin in Combination with S-1, Durvalumab, or Pembrolizumab as First-Line Triple Treatment for Advanced Biliary Tract Cancer.
    Kashiwa M; Maeda H
    J Gastrointest Cancer; 2024 Dec; 55(4):1569-1580. PubMed ID: 39172318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Model-based cost-utility analysis of gemcitabine, cisplatin, and S-1 as triple therapy for advanced biliary tract cancer.
    Kashiwa M; Matsushita R
    Int J Clin Pharm; 2023 Aug; 45(4):875-883. PubMed ID: 37079225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of gemcitabine + cisplatin vs. gemcitabine monotherapy in advanced biliary tract cancer.
    Roth JA; Carlson JJ
    J Gastrointest Cancer; 2012 Jun; 43(2):215-23. PubMed ID: 21234709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Cost-Effectiveness Analysis of Gemcitabine plus Cisplatin Versus Gemcitabine Alone for Treatment of Advanced Biliary Tract Cancer in Japan.
    Tsukiyama I; Ejiri M; Yamamoto Y; Nakao H; Yoneda M; Matsuura K; Arakawa I; Saito H; Inoue T
    J Gastrointest Cancer; 2017 Dec; 48(4):326-332. PubMed ID: 27785685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy.
    Patterson K; Prabhu V; Xu R; Li H; Meng Y; Zarabi N; Zhong Y; Batteson R; Pellissier J; Keefe S; Grivas P; de Wit R
    Eur Urol Oncol; 2019 Sep; 2(5):565-571. PubMed ID: 31412011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic Evaluation of Cisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine for the Treatment of First-Line Advanced Metastatic Triple-Negative Breast Cancer in China: Using Markov Model and Partitioned Survival Model.
    Rui M; Shi F; Shang Y; Meng R; Li H
    Adv Ther; 2020 Sep; 37(9):3761-3774. PubMed ID: 32647912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
    Abdel-Rahman O; Elsayed Z; Elhalawani H
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-institution experience with gemcitabine-cisplatin combination therapy as a second-line treatment for patients with unresectable biliary tract cancer after failure of gemcitabine-S-1 combination therapy: a prospective feasibility study.
    Matsuyama R; Morioka D; Mori R; Hiratani S; Yabushita Y; Ota Y; Kumamoto T; Taniguchi K; Endo I
    Cancer Chemother Pharmacol; 2018 May; 81(5):949-955. PubMed ID: 29594362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer.
    Inoue H; Todaka A; Yamazaki K; Fushiki K; Shirasu H; Kawakami T; Tsushima T; Hamauchi S; Yokota T; Machida N; Fukutomi A; Onozawa Y; Andoh A; Yasui H
    Invest New Drugs; 2021 Oct; 39(5):1399-1404. PubMed ID: 33835357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toripalimab plus chemotherapy in American patients with recurrent or metastatic nasopharyngeal carcinoma: A cost-effectiveness analysis.
    Lian D; Gan Y; Xiao D; Xuan D; Chen Y; Yang Y
    Cancer Med; 2024 May; 13(10):e7243. PubMed ID: 38752448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study.
    Oh DY; He AR; Bouattour M; Okusaka T; Qin S; Chen LT; Kitano M; Lee CK; Kim JW; Chen MH; Suksombooncharoen T; Ikeda M; Lee MA; Chen JS; Potemski P; Burris HA; Ostwal V; Tanasanvimon S; Morizane C; Zaucha RE; McNamara MG; Avallone A; Cundom JE; Breder V; Tan B; Shimizu S; Tougeron D; Evesque L; Petrova M; Zhen DB; Gillmore R; Gupta VG; Dayyani F; Park JO; Buchschacher GL; Rey F; Kim H; Wang J; Morgan C; Rokutanda N; Żotkiewicz M; Vogel A; Valle JW
    Lancet Gastroenterol Hepatol; 2024 Aug; 9(8):694-704. PubMed ID: 38823398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of nivolumab plus gemcitabine-cisplatin as first-line treatment for advanced urothelial carcinoma in China and the United States.
    Xiang G; Huang Y; Gan L; Wang L; Ding Y; Wu Y; Xing H; Liu Y
    Front Immunol; 2024; 15():1426024. PubMed ID: 39346914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population.
    Rimini M; Fornaro L; Rizzato MD; Antonuzzo L; Rossari F; Satake T; Vandeputte H; Vivaldi C; Pressiani T; Lucchetti J; Kim JW; Abidoye O; Rapposelli IG; Tamberi S; Finkelmeier F; Giordano G; Nichetti F; Chon HJ; Braconi C; Pirrone C; Castet F; Tamburini E; Yoo C; Parisi A; Diana A; Scartozzi M; Prager GW; Avallone A; Schirripa M; Kim IH; Perkhofer L; Oneda E; Verrico M; Adeva J; Chan SL; Spinelli GP; Personeni N; Garajova I; Rodriquenz MG; Leo S; Salani F; De Rosa A; Lavacchi D; Foti S; Ikeda M; Dekervel J; Niger M; Balsano R; Tonini G; Kang M; Bekaii-Saab T; Esposito L; Boccaccino A; Himmelsbach V; Landriscina M; Djaballah SA; Zanuso V; Masi G; Lonardi S; Rimassa L; Casadei-Gardini A
    Eur J Cancer; 2024 Sep; 208():114199. PubMed ID: 39002348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Tumor Shrinkage Pattern with Biweekly Triplet Gemcitabine+Cisplatin+S-1 Regimen for Biliary Tract Cancers: Implications for Neoadjuvant Therapy from the Data of KHBO1401 (KHBO1401-1A Study).
    Kobayashi S; Wada H; Sakai D; Baba H; Kanai M; Kamachi H; Takayama T; Ueno M; Takahashi M; Sho M; Yoshimura K; Hatano E; Nagano H; Ioka T;
    Oncology; 2024; 102(6):447-456. PubMed ID: 38048759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study.
    Rimini M; Masi G; Lonardi S; Nichetti F; Pressiani T; Lavacchi D; Jessica L; Giordano G; Scartozzi M; Tamburini E; Pastorino A; Rapposelli IG; Daniele B; Martinelli E; Garajova I; Aprile G; Schirripa M; Formica V; Salani F; Winchler C; Bergamo F; Balsano R; Gusmaroli E; Lorenzo A; Landriscina M; Pretta A; Toma I; Pirrone C; Diana A; Leone F; Brunetti O; Brandi G; Garattini SK; Satolli MA; Rossari F; Fornaro L; Niger M; Zanuso V; De Rosa A; Ratti F; Aldrighetti L; De Braud F; Foti S; Rizzato MD; Vivaldi C; Stefano C; Rimassa L; Antonuzzo L; Casadei-Gardini A
    Target Oncol; 2024 May; 19(3):359-370. PubMed ID: 38691295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Durvalumab: A Review in Advanced Biliary Tract Cancer.
    Fung S; Syed YY
    Target Oncol; 2023 Nov; 18(6):965-972. PubMed ID: 37943483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002).
    Kanai M; Hatano E; Kobayashi S; Fujiwara Y; Marubashi S; Miyamoto A; Shiomi H; Kubo S; Ikuta S; Yanagimoto H; Terajima H; Ikoma H; Sakai D; Kodama Y; Seo S; Morita S; Ajiki T; Nagano H; Ioka T
    Cancer Chemother Pharmacol; 2015 Feb; 75(2):293-300. PubMed ID: 25477010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. S-1 or gemcitabine adjuvant therapy in resected pancreatic cancer: a cost-effectiveness analysis based on the JASPAC-01 trial.
    Liao W; Huang J; Zhu G; Zhou J; Wen F; Zhang P; Zhou K; Wu Q; Wang X; Gou H; Li Q
    Expert Rev Pharmacoecon Outcomes Res; 2020 Feb; 20(1):133-138. PubMed ID: 31597496
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost-effectiveness analysis of adding durvalumab to chemotherapy as first-line treatment for advanced biliary tract cancer based on the TOPAZ-1 trial.
    Zhao Q; Xie R; Zhong W; Liu W; Chen T; Qiu X; Yang L
    Cost Eff Resour Alloc; 2023 Mar; 21(1):19. PubMed ID: 36859267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of combination chemotherapy with gemcitabine, cisplatin, and S-1 in patients with advanced biliary tract cancer.
    Watanabe A; Kida M; Miyazawa S; Iwai T; Okuwaki K; Kaneko T; Yamauchi H; Takezawa M; Imaizumi H; Koizumi W
    World J Gastroenterol; 2015 May; 21(19):5979-84. PubMed ID: 26019463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.